About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

A Study of NGM282 in Patients With Primary Sclerosing Cholangitis

NCT02704364·38 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

NGM Biopharmaceuticals, Inc

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Confirmed diagnosis of PSC

You may not be if

Clinically significant acute or chronic liver disease of an etiology other than PSC
Secondary or IgG4 related sclerosing cholangitis

The record

StatusCompleted

PhasePhase 2

Taking part62

StartedMar 2016

UpdatedJun 17, 2025

Conditions

Primary Sclerosing Cholangitis

Where38

NGM Clinical Study Site 118
Sacramento, California, United States
NGM Clinical Study Site 112
San Clemente, California, United States
NGM Clinical Study Site 127
San Francisco, California, United States